Neovasc Inc. (NVCN): Price and Financial Metrics
NVCN Price/Volume Stats
| Current price | $30.03 | 52-week high | $30.07 |
| Prev. close | $29.54 | 52-week low | $4.59 |
| Day low | $29.43 | Volume | 45,401 |
| Day high | $30.07 | Avg. volume | 56,993 |
| 50-day MA | $28.96 | Dividend yield | N/A |
| 200-day MA | $14.15 | Market Cap | 82.37M |
NVCN Stock Price Chart Interactive Chart >
Neovasc Inc. (NVCN) Company Bio
Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.
Latest NVCN News From Around the Web
Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.
Why Shares of Shockwave Medical Jumped on TuesdayShares of Shockwave Medical (NASDAQ: SWAV) were up 10.69% early Tuesday afternoon after the Centers for Medicare and Medicaid Services (CMS) unveiled a proposed rule that detailed new payment codes for coronary intravascular lithotripsy (IVL), which is performed by a system that Shockwave manufactures. Shockwave's IVL uses sonic pressure waves to break up hardened plaque in arteries. Not only do the proposed new codes mean more money for Shockwave -- an estimated $4,000 to $5,000 more per procedure -- but it also shows that the CMS is recognizing the value of the IVL. |
Shockwave Medical Completes Acquisition of NeovascSANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”). The Neovasc Reducer System (the “Reducer”) is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a |
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate UpdateVANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth against the fourth quarter of 2021), and $3.8 million for the full year 2022 (49% growth against fiscal 2021). · On March 13, 2023, following the conclusion of oral a |
Neovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last yearThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you... |
Neovasc Shareholders Approve Acquisition by Shockwave MedicalVancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement |
NVCN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | 1.66% |
| 1-year | 347.54% |
| 3-year | -43.87% |
| 5-year | -95.38% |
| YTD | 90.12% |
| 2022 | 34.83% |
| 2021 | -50.76% |
| 2020 | -82.41% |
| 2019 | -9.83% |
| 2018 | -99.00% |
Continue Researching NVCN
Want to do more research on Neovasc Inc's stock and its price? Try the links below:Neovasc Inc (NVCN) Stock Price | Nasdaq
Neovasc Inc (NVCN) Stock Quote, History and News - Yahoo Finance
Neovasc Inc (NVCN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...